Skip to content

Clinical study on the effectiveness and safety of Jiajia Shenfu Longmu Decoction in patients with acute myocardial infarction

Clinical study on the effectiveness and safety of Jiajia Shenfu Longmu Decoction in patients with acute myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000691
Enrollment
Unknown
Registered
2026-03-23
Start date
2026-03-31
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

control:Basic Western Medical Treatment
Teratment:Basic Western Medicine Treatment Combined with Shenfu Longmu Decoction

Sponsors

zongjun liu Putuo Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the "Guidelines for the Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndrome (2024)" formulated by the Cardiovascular Society of the Chinese Medical Association in 2024 and the "Acute Coronary Syndrome (ACS) Patients" issued by the American College of Cardiology/American Heart Association in 2025. "Management Guidelines for Patients" to study and formulate diagnostic standards for acute myocardial infarction; (2) At least two chief physicians in traditional Chinese medicine diagnose the TCM syndrome as heart and kidney yang deficiency syndrome; (3) Aged 18-80 years old, no gender limit; (4) Voluntarily participate in this clinical trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) People with heart diseases such as cardiomyopathy, valvular disease or congenital heart disease, myocardial bridge; (2) People with other critical and severe systemic diseases, such as malignant tumors, severe lung infections, reduced lung function affecting daily life, liver and kidney failure, advanced cancer, autoimmune diseases, etc. (3) People with a history of mental illness, intellectual disability, mobility issues or other restrictions on the collection of information related to this study; (4) Women who are pregnant or lactating, or those who plan to become pregnant during the study.

Design outcomes

Primary

MeasureTime frame
Cardiac troponin T;N-terminal pro-B-type natriuretic peptide;

Secondary

MeasureTime frame
Soluble Suppression of Tumorigenicity 2;Heart ultrasound;Killip class;Global Registry of Acute Coronary Events Risk Score;electrocardiogram;Coronary Computed Tomography Angiography;Myocardial enzyme spectrum;Traditional Chinese Medicine Syndrome Score;High-sensitivity C-reactive Protein;blood lipids;Blood Glucose;

Countries

china

Contacts

Public ContactZongjun liu

Putuo Hospital, Shanghai University of Traditional Chinese Medicine

Liuzongjun1548@shutcm.edu.cn19821577439

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026